Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

OPDP slams print ad in Untitled Letter

OPDP slams print ad in Untitled Letter

The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Court clears the way for Celebrex generics

Court clears the way for Celebrex generics

Ruling voids FDA's take on reissued patents, settling a year of challenges by generic applicants

FDA issues long-awaited plan for electronic labeling

The much hashed-over initiative would require pharma firms to distribute the professional insert electronically.

Lions Health announces 2015 jury presidents

The annual awards show, celebrating creativity in marketing communications, has named Langland's executive creative director and Sudler & Hennessey chief creative officer to lead the jury.

Five things for pharma marketers to know: Thursday, December 17

Five things for pharma marketers to know: Thursday, December 17

UCB generic deal falls through; agency hiring could spike in 2015; teenage prescription drug abuse is on the decline.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters